July 29, 2015 – Boulder, Colo. (USA) and Schlieren, Zurich (CH) – Biodesix, Inc., a molecular diagnostics company that discovers and commercializes blood-based diagnostic tests to improve outcomes for patients with cancer, and Biognosys AG, a leader in next-gen proteomics, today announced that Biodesix® will begin offering Biognosys’ HRM technology as part of its companion diagnostic development capabilities to develop novel protein assays for the oncology market.
As Biodesix continues to expand its collaborations with pharmaceutical companies and key opinion leaders in oncology to bring novel blood-based tests to market, the inclusion of Biognosys’ technology will offer new ways to rapidly discover biomarkers with Biodesix’ proven analytical platform. Biognosys’ HRM-MS™, the next generation high-content proteomics technology, provides reproducible and accurate quantification of thousands of proteins and helps researchers identify clinically meaningful differences between specific groups of patients. Compared to other mass spectrometry labeling approaches, the sample preparation is much simpler (no chemistry involved, no fractionation necessary) and there are no limitations on the number of samples that can be analyzed.
The foundation of Biodesix’ proteomic tests is based on combining deep MALDI-TOF mass spectrometry data with deep learning principles to extract the relevant molecular information from patient blood samples and correlating it to clinical outcomes. With the addition of HRM-MS technology, Biodesix gains the ability to develop and validate a wider array of diagnostic tests and companion diagnostics, as well as a way to understand the biology contained within tests developed via the hypothesis-independent methodology.
Biodesix has two fully commercialized tests, GeneStrat™ and VeriStrat®, which provide oncologists with clinically relevant information about the patient’s tumor profile and disease aggressiveness within 72 hours. The company’s test development efforts are focused on addressing clinical unmet needs in oncology, utilizing a range of platforms including MALDI-TOF mass spectrometry, droplet digital PCR and NGS and now HRM-MS technology.
“HRM-MS technology is a tool to help Biodesix decipher actionable signals in patients’ blood, helping physicians choose the right therapy based on the patient’s molecular signature. Biognosys’ HRM technology ideally complements our hypothesis-independent approach,” said Biodesix’ CEO, David Brunel. “This collaboration gives us access to cutting edge mass spectrometric technology that will further advance our ability to develop assays, now including those that rely on high-content protein quantification.”
“By combining our proven and comprehensive protein quantification technology with Biodesix’ understanding of the clinical research and diagnostics market, we can identify more clinically relevant classifiers and biomarkers,” said Oliver Rinner, Biognosys’ CEO. “We are excited to team up with Biodesix and strive to be the company that provides the best possible solutions to support researchers in their protein analysis needs.”
Biodesix® is a molecular diagnostics company advancing the development of innovative bloodbased tests for precision medicine in oncology. The company currently has two commercialized tests available to clinicians, GeneStrat™ and VeriStrat®. Used for tumor profiling, GeneStrat is an a la carte gene panel of clinically actionable mutations. VeriStrat, a serum proteomic test, provides physicians with prognostic and predictive information to improve treatment decisions. Biodesix discovers, develops and commercializes diagnostic tests for earlier disease detection, more accurate diagnosis, disease monitoring and better therapeutic guidance, leading to improved patient outcomes. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve the utility of therapeutic agents.
For more information about Biodesix, please visit www.Biodesix.com.
Biognosys is the leading company in next-generation proteomics, offering services and products for precise high-content protein quantification. At Biognosys we believe that the decoding of the proteome will impact life science more than the genome revolution a decade ago. Our mission is to make next-generation proteomics widely available with our contract research services and with our portfolio of innovative reagents and software products. Our technology quantifies proteins with unbeatable precision and depth. The solution is based on high-resolution mass spectrometry with a novel parallel signal processing approach for quantification of large proteomes in a single experiment.
For more information about Biognosys, please visit www.biognosys.ch.
Contact for Biodesix:
Contact for Biognosys:
Stephan van Sint Fiet
+41 78 677 99 20